HIGHBuilt-inProduct / Revenue mix
two products (bempedoic acid, bempedoic acid/ezetimibe tablet)
“10-K Item 1A: 'We depend almost entirely on the success of two products, bempedoic acid and the bempedoic acid / ezetimibe combination tablet.'”
ESPR · Concentration risk · 10-K extracted
Esperion Therapeutics (ESPR) concentration risks
Updated
The most significant concentration Esperion Therapeutics discloses is two products (bempedoic acid, bempedoic acid/ezetimibe tablet), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Esperion Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
sole source third-party manufacturers
“10-K Item 1A: 'We may rely on sole source third-party suppliers to manufacture and supply bempedoic acid, the bempedoic acid / ezetimibe combination tablet'”
MEDIUMOutside partySupplier
ezetimibe supply
“10-K Item 1A: 'is dependent on the continued availability of ezetimibe in the marketplace, and there can be no assurance that the current availability of ezetimibe will continue'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Esperion's concentration risk stacks structural and supply dependencies on top of each other. The company depends almost entirely on the success of two products, bempedoic acid and the bempedoic acid/ezetimibe combination tablet — a structural feature disclosed at a high share, meaning the entire commercial thesis rests on this narrow product base rather than a diversified portfolio. Compounding that, the company may rely on sole source third-party suppliers to manufacture and supply both products, also disclosed at a high share — so not only is revenue concentrated in two products, but production of those products runs through manufacturers with no disclosed alternative. A third, comparatively smaller dependency concerns the continued availability of ezetimibe in the marketplace, with no assurance current availability will continue, at a medium disclosed share. These three exposures compound rather than offset each other: a disruption at either sole-source manufacturer, or an ezetimibe supply issue, would hit a product base that is already narrow by design. For an investor, this is the kind of stacked structural-plus-dependency profile that could plausibly move a verdict, since there's no diversification cushion anywhere in the chain — product, manufacturing, and raw-material supply are all concentrated together.
For the engine’s reasoning on ESPR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| ESPR● | Esperion Therapeutics, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.